OR WAIT null SECS
January 02, 2024
Clarivate has released its 2024 Drugs to Watch report, highlighting 13 therapies with great potential.
GSI shortages result from how hospitals buy GSI drugs, and the underinvestment in manufacturing operations that follow.
December 29, 2023
Clinician-Scientists are vital innovation spark plugs, accounting for 40% of Nobel awards in Physiology or Medicine, and two thirds of Big Pharma CSOs.
Through Syena, its oncology-focused product company, Replay will develop and manufacture T-cell receptor and natural killer cell therapies with the NIH and Miltenyi Biotec.
December 28, 2023
Is increasing molecular diversity pushing manufacturing ecosystem consolidation toward turnkey solutions?
Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.
December 27, 2023
The midterm report of the European Medicines Agencies Network Strategy finds that the network has strengthened and is on track to achieve its objectives.
Andelyn Biosciences has been selected by Ultragenyx to manufacture UX111, that company’s gene therapy for treating Sanfilippo Syndrome.
December 26, 2023
WHO provides a look at the world’s health as the agency turns 75.
December 21, 2023
The final guidance document provides recommendations for designing a new registry or using an existing registry to support decisions regarding safety and effectiveness of a drug.